Gene Therapy to Treat Cancer for First Time
By Press Trust of India,
Press Trust of India
| 06. 19. 2008
In the first case of its kind, doctors have treated a cancer patient by injecting him with billions of his own immune cells, a development that projects the huge power of gene therapy for the killer disease.
According to reports in the New England Journal of Medicine, US researchers treated a 52-year-old man of melanoma by cloning cells from the patients own defence system and injecting them back into his body, in a process known as "immunotherapy".
The man was free from tumours within eight weeks of undergoing the procedure. After two years he is still free from the disease which had spread to his lymph nodes and one of his lungs. "For this patient we were successful, but we would need to confirm the effectiveness of therapy in a larger study," Dr Cassian Yee, who led the team at the Fred Hutchinson Cancer Research Centre in Seattle.
The treatment, which is extremely expensive at this stage of development, showed that vast numbers of immune cells in the body can be safely and effectively used to treat skin cancer, The...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
